Urinary Tract Infections – Drug Pipeline Analysis and Market Forecasts to 2016
Urinary Tract Infections – Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialist’s new report, “Urinary Tract Infections (UTI) – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global urinary tract infections market. The report identifies the key trends shaping and driving the global urinary tract infections market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global urinary tract infections sector.
GlobalData’s analysis suggests that the global Urinary Tract Infection (UTI) market was worth 1.5m in 2009. The market is expected to be driven by an increase in the usage of newly launched antibiotics for the treatment of complicated UTIs and an increase in the prevalence and diagnosis of UTIs. The patent expiry of one of the most efficacious drug, Levaquin, in 2010 is expected to drive market revenues down. The impact of patent expiry is expected to be softened by the increase in revenue contribution of recently launched carbapenems for the treatment of complicated UTIs.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
Scope
The scope of the report includes:
• Annualized global urinary tract infections market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data split across different phases by mechanism of action and emerging trends. Key classes of antibiotics in the pipeline include fluoroquinolones, cephalosporins and beta-lactams. It also includes beta-lactamase inhibitors, vaccines and a stable analog of N,N-dichlorotaurine.
• Analysis of the current and future competition in the global UTIs market. Key market players covered include Osel Inc, Cubist Pharmaceuticals, Novexel Inc (AstraZeneca), MerLion Pharmaceuticals GmbH, Tedec-Meiji Farma, S.A. and NovaBay Pharmaceuticals, Inc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future of the UTI market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global urinary tract infections market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global urinary tract infections market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global urinary tract infections market landscape? – Identify, understand and capitalize.
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Urinary Tract Infections Market: Market Characterization 6
2.1 Overview 6
2.2 Urinary Tract Infections Market Size 6
2.3 Urinary Tract Infections Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Urinary Tract Infections Market 8
2.4.1 Drivers for the UTI Market 8
2.4.2 Barriers for the UTI Market 9
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Urinary Tract Infections Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profiles of the Major Marketed Products in the Urinary Tract Infections Market 12
3.3.1 Doribax (Doripenem) 12
3.3.2 Ciprofloxacin 13
3.3.3 Levaquin (levofloxacin) 14
3.3.4 Monurol (fosfomycin tromethamine) 16
3.3.5 Macrobid (Nitrofurantoin) 17
3.3.6 Bactrim/Septra (trimethoprim/sulfamethoxazole) 17
3.4 Key Takeaway 19
4 Urinary Tract Infections Market: Pipeline Assessment 20
4.1 Overview 20
4.2 Strategic Pipeline Assessment 20
4.2.1 Technology Trends Analytic Framework 20
4.3 Urinary Tract Infections – Promising Drugs Under Clinical Development 21
4.4 Molecule Profile for Promising Drugs Under Clinical Development 22
4.4.1 CXA-101 22
4.4.2 NXL104/ceftazidime 22
4.4.3 Finafloxacin 23
4.5 Urinary Tract Infections Market – Clinical Pipeline by Mechanism of Action 23
4.6 Urinary Tract Infections Pipeline – Pipeline by Clinical Phases of Development 24
4.6.1 Urinary Tract Infections Therapeutics – Phase III Clinical Pipeline 25
4.6.2 Urinary Tract Infections Therapeutics – Phase II Clinical Pipeline 25
4.6.3 Urinary Tract Infections Therapeutics – Preclinical Clinical Pipeline 25
4.6.4 Discontinued / Suspended Drugs for Urinary Tract Infection 25
4.7 Key Takeaway 26
5 Urinary Tract Infections Market: Implications for Future Market Competition 27
6 Urinary Tract Infections Market: Future Players in the Urinary Tract Infections Market 29
6.1 Introduction 29
6.2 Osel Inc. 29
6.2.1 Company Overview 29
6.2.2 Urinary Tract Infections Portfolio 30
6.3 Cubist Pharmaceuticals 30
6.3.1 Company Overview 30
6.3.2 Business Description 30
6.3.3 Urinary Tract Infections Portfolio 31
6.4 Novexel SA 31
6.4.1 Company Overview 31
6.4.2 Urinary Tract Infections Portfolio 31
6.5 MerLion Pharmaceuticals Pte Ltd 31
6.5.1 Company Overview 31
6.5.2 Urinary Tract Infections Portfolio 32
7 Urinary Tract Infections Market: Appendix 33
7.1 Market Definition 33
7.2 Abbreviations 33
7.3 Research Methodology 33
7.3.1 Coverage 34
7.3.2 Secondary Research 34
7.3.3 Forecasting 35
7.3.4 Primary Research 38
7.3.5 Expert Panels 38
7.4 Contact Us 38
7.5 Disclaimer 38
7.6 Sources 39
1.1 List of Tables
Table 1: Global Urinary Tract Infections Market Forecast ($ m), 2001–2009 7
Table 2: Global Urinary Tract Infections Market Forecast ($ m), 2009–2016 8
Table 3: Marketed Product Analysis in the Urinary Tract Infections Market, 2010 18
Table 4: Urinary Tract Infections – Most Promising Drugs Under Clinical Development, 2010 21
Table 5: Urinary Tract Infections Pipeline, Phase III, 2010 25
Table 6: Urinary Tract Infections Pipeline, Phase II, 2010 25
Table 7: Urinary Tract Infections Pipeline, Preclinical, 2010 25
Table 8: Urinary Tract Infections Pipeline, Discontinued / Suspended Drugs, 2010 25
Table 9: Osel Inc. – Urinary Tract Infections Pipeline, 2010 30
Table 10: Cubist Pharmaceuticals – Urinary Tract Infections Pipeline, 2010 31
Table 11: Novexel SA – Urinary Tract Infections Pipeline, 2010 31
Table 12: MerLion Pharmaceuticals Pte Ltd – Urinary Tract Infections Pipeline, 2010 32
1.2 List of Figures
Figure 1: Global Urinary Tract Infections Market Revenues ($ m), 2001–2009 7
Figure 2: Global Urinary Tract Infections Market Forecast ($ m), 2009–2016 8
Figure 3: Opportunity and Unmet Need in the Urinary Tract Infections Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Marketed Products for Urinary Tract Infection, 2010 12
Figure 5: Technology Trends Analytic Framework of the Urinary Tract Infections Pipeline, 2010 20
Figure 6: Technology Trends Analytic Framework of the Urinary Tract Infections Pipeline – Description, 2010 21
Figure 7: Urinary Tract Infections Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 24
Figure 8: Urinary Tract Infections Pipeline by Phase of Clinical Development, 2010 24
Figure 9: Implications for Future Market Competition in the Urinary Tract Infections Market, 2010 27
Figure 10: Urinary Tract Infections Therapeutics Market – Clinical Pipeline by Company, 2010 29
Figure 11: GlobalData Methodology 34
Figure 12: GlobalData Market Forecasting Model 37
Find More Urinary Articles
Tags: 2016, Analysis, drug, Forecasts, Infections, Market, Pipeline, Tract, Urinary
cheap drugs such as Naltrexone May Ease Fibromyalgia Symptoms
April 17, 2009 — An inexpensive drug called naltrexone may make a good treatment for fibromyalgia, report researchers at Stanford University.
Naltrexone isn’t a new drug; it’s been around for more than 30 years and is used to treat opioid addiction.
Stanford’s Jarred Younger, PhD, and Sean Mackey, MD, PhD, tested a low dose of naltrexone as a fibromyalgia treatment in 10 women who had had fibromyalgia for about 10 years, on average.
First, the women spent two weeks recording the severity of their fibromyalgia symptoms every day using a handheld computer. And they took lab tests to gauge their fibromyalgia pain and sensitivity to heat and cold.
After that, the women took a placebo pill every day for two weeks, but they didn’t know it was a placebo pill. At the end of the placebo period, the women took a naltrexone pill once a day for eight weeks. Finally, they spent the last two weeks of the study not taking naltrexone or the placebo.
All along, the women continued to rate their fibromyalgia symptoms every day, and they repeated their lab tests every two weeks.
While taking the placebo, the women reported a 2.3% drop in the severity of their fibromyalgia symptoms, compared to their symptom ratings at the start of the study.
When they switched from the placebo to naltrexone, they reported an additional 30% drop in their fibromyalgia symptom severity.
The women also showed greater tolerance for pain and for hot (but not cold) temperatures while taking naltrexone.
Most of the women — six out of 10 — responded to naltrexone.
Side effects were mild and brief.
Two women reported having more vivid dreams during the study, and one woman reported transient nausea and insomnia during the first few nights of taking the pills, note Younger and Mackey.
The study, which appears online in Pain Medicine, was a small, preliminary project to see if low-dose naltrexone showed promise. It did, so Younger and Mackey are already working on a new study that will test low-dose naltrexone in 30 fibromyalgia patients for 16 weeks.
